|
|
|
Fri 12 Feb 2016
Close: 12 025c 
Day's move: 0c (0.00%)
Volume: 0
Trades: 0
|
|
|
|
Revenue for the interim period ended 30 September 2015 increased by 16% to R19.6 billion (2013: R16.8 billion). Operating profit rose to R3.0 billion (2014: R2.6 billion), while profit attributable to equity holders of the company jumped to R1.9 billion (2014: R1.7 billion). Furthermore, headline earnings per share grew by 16% to 213.8cps (2014: 184.4cps).
Dividend
Notice is hereby given that the directors have declared an interim gross cash dividend in respect of the period under review of 36.0 cents (2014: 31.0 cents) (30.60 cents (2014: 26.35 cents) net of dividend withholding tax) per ordinary share.
Overview and outlook
Notwithstanding the ongoing changes in the global and regional economies and the regulatory changes that continue to impact healthcare and its affordability, we are continuing to see a strong demand for quality private healthcare services in our three operating platforms. The trend is also prevalent in the UK, where during the period we acquired a 29.9% stake in Spire Healthcare Group plc, a leading provider of private healthcare, with 39 private hospitals.
Mediclinic International has continued to deliver strong revenue and profit growth. Our three operating platforms in Southern Africa, the Middle East and Switzerland have all achieved good growth in patient numbers and we continue to invest in buildings, technology and people to ensure we offer high quality private healthcare services to both in and out-patients.
The Group’s earnings which are reported in South African rand, were again positively impacted by currency movements Our Swiss, Middle East and UK platforms contributed 66% of adjusted normalised headline earnings.
Our focus is to ensure that our patients come first, that we continuously improve our value proposition in terms of technology, care and the latest improvements in medicine and surgery. With three operating platforms and a significant investment in the UK, we can leverage best practice in terms of experience, knowledge and skills. Mediclinic remains well positioned for future growth.
|
| |
| Click here for Results In Brief |
| |
| Click here for Results Analysis |
| Closing price data source: JSE Ltd. All other statistics calculated by ProfileData. |
|
|
